News & Analysis on Clinical Trial Services & Contract Research And Development
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
Charm Therapeutics has announced investment from NVentures – NVIDIA’s venture investment arm. This represents a major milestone for Charm and means it will be able to deliver more on its research and development (R&D) activities for novel oncology medicines.